Advanced search
Start date

Modulation study of anti-inflammatory protein Annexin A1 in cervical cancer

Grant number: 16/07605-3
Support Opportunities:Scholarships in Brazil - Scientific Initiation
Effective date (Start): July 01, 2016
Effective date (End): December 31, 2016
Field of knowledge:Biological Sciences - Morphology - Cytology and Cell Biology
Principal Investigator:Flávia Cristina Rodrigues Lisoni
Grantee:Thaís Bravo Picão
Host Institution: Faculdade de Engenharia (FEIS). Universidade Estadual Paulista (UNESP). Campus de Ilha Solteira. Ilha Solteira , SP, Brazil


The cervical cancer is the second type of more frequent cancer in women world-wide, being the fourth cause of death for cancer in developing countries. Cervical carcinogenesis is related with genetic alterations, infection for Human PapilomaVirus (HPV), angiogenesis and inflammatory processes. The idea of that the inflammation is involved in tumorigenesis is supported by the comment of that the cancer appears frequently in areas of chronic inflammation. On the other hand, the inflammatory reply is controlled for the action of anti-inflammatory mediators, who act to keep the homeostasis of the immunological reply to prevent the tecidual injury. Among these mediators we detach the annex in A1 (ANXA1), protein of 37 kDa, that is express for the tumoral cells and acts as modulating of the inflammatory process. However, the molecular mechanisms for which the ANXA1 modulates the cellular answers in the inflammatory processes are not yet completely determined. The available data suggest that this protein family can have, beyond its important role in the inflammatory process, a significant involvement in the cancer, through signaling cascades that include genes related with the cellular cycle, the differentiation and apoptosis. Ahead of these considerations, we will investigate, in vitro, the influence of this anti-inflammatory in the HeLa cells on the morphology, cellular proliferation and migration, observing as the ANXA1 modulates these alterations that can participate of the inflammatory and tumorigenic process. For this, the cell line HeLa (derived from the cervical cell adenocarcinoma) will be used, treated with ANXA1 peptide for 2, 4, 24, 48, 72 and 120 hours. Then, we can get more information about this anti-inflammatory protein acting and directing future individual's genetics therapy.

News published in Agência FAPESP Newsletter about the scholarship:
Articles published in other media outlets (0 total):
More itemsLess items

Please report errors in scientific publications list using this form.